Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

about

Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

Item

http://www.wikidata.org/entity/Q57114269

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в березні 2018

@uk

name

Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

@en

Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

@nl

type

Item

label

Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

@en

Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

@nl

prefLabel

Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

@en

Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

@nl

P1476

Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

@en

P2093

Alexandra von Au

http://www.w3.org/2001/XMLSchema#string

Christof Sohn

http://www.w3.org/2001/XMLSchema#string

Christoph Domschke

http://www.w3.org/2001/XMLSchema#string

Florian Schütz

http://www.w3.org/2001/XMLSchema#string

Frederik Marmé

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.

Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective

NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.

Recent advances in the development of breast cancer vaccines.

Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.

Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.

Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.

A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.

P304

22-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000486330

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29950963

http://www.w3.org/2001/XMLSchema#string

P932

6016061

http://www.w3.org/2001/XMLSchema#string